Metastatic renal cell carcinoma to the pancreas and other sites-a multicenter retrospective study

Cassandra Duarte¹, Junxiao Hu¹, Benoit Beuselinck², Justine Panian³, Nicole Weise³, Nazli Dizman⁴, Katharine A Collier⁵, Nityam Rathi⁶, Haoran Li⁶, Roy Elias⁷, Nieves Martinez-Chanza⁸, Tracy L Rose⁹, Lauren C Harshman^{10

11}, Dharmesh Gopalakrishnan¹², Ulka Vaishampayan^{13

14}, Yousef Zakharia¹⁵, Vivek Narayan¹⁶, Benedito A Carneiro¹⁷, Anthony Mega¹⁷, Nirmish Singla⁷, Cheryl Meguid¹, Saby George¹², James Brugarolas⁷, Neeraj Agarwal⁶, Amir Mortazavi⁵, Sumanta Pal⁴, Rana R McKay³, Elaine T Lam¹

Affiliations

¹ University of Colorado Cancer Center, University of Colorado Anschutz Medical Campus, 1665 Aurora Ct. MS F704, Aurora, CO 80045, USA.
² Department of General Medical Oncology, University Hospitals Leuven, KU Leuven, Herestraat 49, 3000 Leuven, Belgium.
³ Moores Cancer Center University of California San Diego, San Diego, CA, USA.
⁴ City of Hope, Duarte, CA, USA.
⁵ The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
⁶ The University of Utah Huntsman Cancer Institute, Salt Lake City, UT, USA.
⁷ University of Texas Southwestern Medical Center, Dallas, TX, USA.
⁸ Institut Jules Bordet, Brussels, Belgium.
⁹ UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA.
¹⁰ Prior Institution: Dana-Farber Cancer Institute, Boston, MA, USA.
¹¹ Current Institution: Surface Oncology, Cambridge, MA, USA.
¹² Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
¹³ Prior Institution: Karmanos Cancer Center, Detroit, MI, USA.
¹⁴ Current Institution: Rogel Cancer Center, University of Michigan, Ann Arbor, MI, USA.
¹⁵ Holden Comprehensive Cancer Center at University of Iowa, Iowa City, IA, USA.
¹⁶ Abramson Cancer Center at the University of Pennsylvania, Philadelphia, PA, USA.
¹⁷ Legorreta Cancer Center at Brown University, Lifespan Cancer Institute, Providence, RI, USA.

PMID: 37304495
PMCID: PMC10248040
DOI: 10.1016/j.eclinm.2023.102018

Metastatic renal cell carcinoma to the pancreas and other sites-a multicenter retrospective study

Cassandra Duarte et al. EClinicalMedicine. 2023.

. 2023 Jun 1:60:102018.

doi: 10.1016/j.eclinm.2023.102018. eCollection 2023 Jun.

Authors

Affiliations

¹ University of Colorado Cancer Center, University of Colorado Anschutz Medical Campus, 1665 Aurora Ct. MS F704, Aurora, CO 80045, USA.
² Department of General Medical Oncology, University Hospitals Leuven, KU Leuven, Herestraat 49, 3000 Leuven, Belgium.
³ Moores Cancer Center University of California San Diego, San Diego, CA, USA.
⁴ City of Hope, Duarte, CA, USA.
⁵ The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
⁶ The University of Utah Huntsman Cancer Institute, Salt Lake City, UT, USA.
⁷ University of Texas Southwestern Medical Center, Dallas, TX, USA.
⁸ Institut Jules Bordet, Brussels, Belgium.
⁹ UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA.
¹⁰ Prior Institution: Dana-Farber Cancer Institute, Boston, MA, USA.
¹¹ Current Institution: Surface Oncology, Cambridge, MA, USA.
¹² Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
¹³ Prior Institution: Karmanos Cancer Center, Detroit, MI, USA.
¹⁴ Current Institution: Rogel Cancer Center, University of Michigan, Ann Arbor, MI, USA.
¹⁵ Holden Comprehensive Cancer Center at University of Iowa, Iowa City, IA, USA.
¹⁶ Abramson Cancer Center at the University of Pennsylvania, Philadelphia, PA, USA.
¹⁷ Legorreta Cancer Center at Brown University, Lifespan Cancer Institute, Providence, RI, USA.

PMID: 37304495
PMCID: PMC10248040
DOI: 10.1016/j.eclinm.2023.102018

Abstract

Background: Metastatic renal cell carcinoma (mRCC) is a heterogenous disease with poor 5-year overall survival (OS) at 14%. Patients with mRCC to endocrine organs historically have prolonged OS. Pancreatic metastases are uncommon overall, with mRCC being the most common etiology of pancreatic metastases. In this study, we report the long-term outcomes of patients with mRCC to the pancreas in two separate cohorts.

Methods: We performed a multicenter, international retrospective cohort study of patients with mRCC to the pancreas at 15 academic centers. Cohort 1 included 91 patients with oligometastatic disease to the pancreas. Cohort 2 included 229 patients with multiples organ sites of metastases including the pancreas. The primary endpoint for Cohorts 1 and 2 was median OS from time of metastatic disease in the pancreas until death or last follow up.

Findings: In Cohort 1, the median OS (mOS) was 121 months with a median follow up time of 42 months. Patients who underwent surgical resection of oligometastatic disease had mOS of 100 months with a median follow-up time of 52.5 months. The mOS for patients treated with systemic therapy was not reached. In Cohort 2, the mOS was 90.77 months. Patients treated with first-line (1L) VEGFR therapy had mOS of 90.77 months; patients treated with IL immunotherapy (IO) had mOS of 92 months; patients on 1L combination VEGFR/IO had mOS of 74.9 months.

Interpretations: This is the largest retrospective cohort of mRCC involving the pancreas. We confirmed the previously reported long-term outcomes in patients with oligometastatic pancreas disease and demonstrated prolonged survival in patients with multiple RCC metastases that included the pancreas. In this retrospective study with heterogeneous population treated over 2 decades, mOS was similar when stratified by first-line therapy. Future research will be needed to determine whether mRCC patients with pancreatic metastases require a different initial treatment strategy.

Funding: Statistical analyses for this study were supported in part by the University of Colorado Cancer Center Support Grant from the NIH/NCI, P30CA046934-30.

Keywords: Immunotherapy; Metastatic renal cell carcinoma; Pancreatic metastases; VEGFR.

PubMed Disclaimer

Conflict of interest statement

ETL has received institutional research support from Amgen, Inc., Argos Therapeutics, Arrowhead Pharmaceuticals, Inc., Astellas Pharma, Inc., Bristol Myers Squibb, Biosplice Therapeutics, Inc., Calithera Biosciences, Constellation Pharmaceuticals, Inc., Exelixis, Forma Therapeutics, Genentech/F. Hoffmann-La Roche Ltd, Janssen Pharmaceuticals, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., OnQuality Pharmaceuticals LLC, Peloton Therapeutics, Pfizer, Inc., Promontory Therapeutics, Inc (formerly Phosplatin). AM has received relevant institutional research funding from Acerta Pharma, Genentech, Roche, Merck, Novartis, Seattle Genetics, Astellas Pharma, Mirati Therapeutics, Bristol-Myers Squibb, Debiopharm Group. AM has received consulting fees from Debiopharm Group, Seattle Genetics, Pfizer. LH reports grants to prior institution from Bristol-Myers Squib, Merck, and Takeda. As well as current employment (including stock options) at Surface Oncology outside the submitted work. LH reports advisory or consulting services for Genentech, Pfizer, Corvus, Merck, Exelixis, Novartis, Jounce, Bristol-Myers Squibb, EMD Serrano. LH reports honoraria for lectures/presentations for Michael J Hennessy Associates (Healthcare Communications Company and several brands such as OncLive and PER), ASIM CME, and Ology Medical Education. LH receives support from Genentech for travel outside of the submitted work. JB reports relevant institutional research funding from University of Texas Southwestern Medical Center SPORE in Kidney Cancer (NIH P50 CA196516). NA reports consulting fees from Astellas, Astra Zeneca, Aveo, Bayer, Bristol Myers Squibb, Calithera, Clovis, Eisai, Eli Lilly, EMD Serono, Exelixis, Foundation Medicine, Genentech, Gilead, Janssen, Merck, MEI Pharma, Nektar, Novartis, Pfizer, Pharmacyclics, and Seattle Genetics. NA reports institutional research funding from Astellas, Astra Zeneca, Bavarian Nordic, Bayer, Bristol Myers Squibb, Calithera, Celldex, Clovis, Eisai, Eli Lilly, EMD Serono, Exelixis, Genentech, Gilead, Glaxo Smith Kline, Immunomedics, Janssen, Medivation, Merck, Nektar, New Link Genetics, Novartis, Pfizer, Prometheus, Rexahn, Roche, Sanofi, Seattle Genetics, Takeda, and Tracon. RM reports consulting fees from Aveo, AstraZeneca, Bayer, BMS, Calithera, Caris, Dendreon, Exelixis, JNJ, Novartis, Merck, Myovant, Pfizer, Sanofi, Sorrento Therapeutics, Telix, Tempus. VN reports institutional research funding from Pfizer, Merck, Jenssen, Bristol Myers Squibb. BN reports consulting fees from Merck, Janssen, Myovanat Sciences, Exelixis. BN reports honoraria from Pfizer. ND reports consulting fees from Vivreon Gastrosciences Inc. NM reports participation in data safety monitoring board or advisory board for MDS, Ipsen, BMS, and Astellas. TR reports institutional research funding from National Cancer Institute at the National Institutes of Health (grant number 1K08CA248967-01). SG reports institutional research funding from Aravive, Agensys, Aveo Pharmaceuticals, Bayer, BMS, Calithera Biosciences, Corvus Pharmaceuticals, Eisai, Exelixis Inc, Gilead, Merck, Novartis, Pfizer, Seattle Genetics, and Surface Oncology. SG reports consulting fees from Aveo Pharmaceuticals, Bayer, BMS, Corvus Pharmaceuticals, Eisai, EMD Serono, Exelixis Inc, Merck, Immunomedics, Pfizer, QED Therapeutics, Sanofi, and Seattle Genetics; and honoraria from Aptitude Health, Curio Science, and DAVA Oncology. YZ reports advisory board participation with Bristol Myers Squibb, Amgen, Roche Diagnostics, Novartis, Janssen, Eisai, Exelixis, Castle Bioscience, Genzyme Corporation, Astrazeneca, Array, Bayer, Pfizer, Clovis, EMD serono, Myovant. YZ reports data safety monitoring board participation with Janssen Research and Development. All other authors have nothing to declare.

Figures

**Fig. 1**
**a Cohort 1 Study Population Consort Diagram. b Cohort 2 Study Population Consort Diagram**.

**Fig. 2**
**Kaplan meier curves of overall survival for Cohort 2 total population and by subgroup**.

See this image and copyright information in PMC

References

1. Siegel R.L., Miller K.D., Fuchs H.E., Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7–33. doi: 10.3322/caac.21708. (In eng) - DOI - PubMed
1. Motzer R.J., Escudier B., McDermott D.F., et al. Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial. J Immunother Cancer. 2020;8(2) doi: 10.1136/jitc-2020-000891. (In eng) - DOI - PMC - PubMed
1. Motzer R.J., McDermott D.F., Escudier B., et al. Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma. Cancer. 2022;128(11):2085–2097. doi: 10.1002/cncr.34180. (In eng) - DOI - PMC - PubMed
1. Dudani S., de Velasco G., Wells J.C., et al. Evaluation of clear cell, papillary, and chromophobe renal cell carcinoma metastasis sites and association with survival. JAMA Netw Open. 2021;4(1) doi: 10.1001/jamanetworkopen.2020.21869. (In eng) - DOI - PMC - PubMed
1. Shaya J.A., Lin X., Weise N., et al. Prognostic significance of pancreatic metastases in patients with advanced renal cell carcinoma treated with systemic therapy. Clin Genitourin Cancer. 2021;19:e367–e373. doi: 10.1016/j.clgc.2021.04.006. (In eng) - DOI - PubMed

Grants and funding

P50 CA196516/CA/NCI NIH HHS/United States

LinkOut - more resources

Full Text Sources

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Metastatic renal cell carcinoma to the pancreas and other sites-a multicenter retrospective study

Affiliations

Metastatic renal cell carcinoma to the pancreas and other sites-a multicenter retrospective study

Authors

Affiliations

Abstract

Conflict of interest statement

Figures

References

Grants and funding

LinkOut - more resources

Full Text Sources